Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review

References

• MiyamotoSDuncanGEMarxCELiebermanJATreatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugsMol Psychiatry20051017910415289815
   PubMed Web of Science ®Google Scholar
• SimpsonGMA brief history of depot neurolepticsJ Clin Psychiatry1984455 pt 2346143745
   PubMed Web of Science ®Google Scholar
• HogartyGESchoolerNRUlrichRMussareFFerroPHerronEFluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochlorideArch Gen Psychiatry1979361212831294227340
   PubMed Web of Science ®Google Scholar
• HaddadPMTaylorMNiazOSFirst-generation antipsychotic long-acting injections v oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studiesBr J Psychiatry Suppl200952S20S2819880913
   PubMedGoogle Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• KishimotoTAgarwalVKishiTLeuchtSKaneJMCorrellCURelapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychoticsMol Psychiatry2013181536622124274
   PubMed Web of Science ®Google Scholar
• LlorcaPMPartial compliance in schizophrenia and the impact on patient outcomesPsychiatry Res2008161223524718849080
   PubMed Web of Science ®Google Scholar
• ShulerKMApproaches to improve adherence to pharmacotherapy in patients with schizophreniaPatient Prefer Adherence2014870171424868149
   PubMed Web of Science ®Google Scholar
• TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry2011168660360921362741
   PubMed Web of Science ®Google Scholar
• StahlSMLong-acting injectable antipsychotics: shall the last be first?CNS Spectr201419013524512639
   PubMed Web of Science ®Google Scholar
• ZhornitskySStipEOral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic reviewSchizophr Res Treatment2012201240717122966436
   PubMedGoogle Scholar
• KishimotoTRobenzadehALeuchtCLong-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trialsSchizophr Bull201440119221323256986
   PubMed Web of Science ®Google Scholar
• KishimotoTNittaMBorensteinMKaneJMCorrellCULong-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studiesJ Clin Psychiatry2013741095796524229745
   PubMed Web of Science ®Google Scholar
• NussbaumAMStroupTSPaliperidone palmitate for schizophreniaSchizophr Bull20123861124112722966147
   PubMed Web of Science ®Google Scholar
• NussbaumMStroupTSPaliperidone palmitate for schizophreniaCochrane Database Syst Rev20126CD00829610.1002/14651858.CD008296.pub222696377
   PubMed Web of Science ®Google Scholar
• JanssenInvega Sustenna (Paliperidone Palmitate) Extended-Release Injectable Suspension Prescribing InformationTitusville, NJOrth-McNeil-Janssen Pharmaceuticals, Inc2009
   Google Scholar
• HoughDLindenmayerJPGopalSSafety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophreniaProg Neuropsychopharmacol Biol Psychiatry20093361022103119481579
   PubMed Web of Science ®Google Scholar
• HoughDGopalSVijapurkarULimPMorozovaMEerdekensMPaliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled studySchizophr Res20101162–310711719959339
   PubMed Web of Science ®Google Scholar
• NasrallahHAGopalSGassmann-MayerCA controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophreniaNeuropsychopharmacology201035102072208220555312
   PubMed Web of Science ®Google Scholar
• PandinaGJLindenmayerJPLullJA randomized, placebo- controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaJ Clin Psychopharmacol201030323524420473057
   PubMed Web of Science ®Google Scholar
• AlphsLBossieCASliwaJKMaYWTurnerNOnset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trialAnn Gen Psychiatry20111011221481243
   PubMed Web of Science ®Google Scholar
• BossieCAFuDJSliwaJKMaYWAlphsLTolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trialTher Adv Psychopharmacol20111411112423983935
   PubMedGoogle Scholar
• BossieCASliwaJKMaYWFuDJAlphsLOnset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trialBMC Psychiatry201110117921569242
   PubMed Web of Science ®Google Scholar
• LiHRuiQNingXXuHGuNA comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophreniaProg Neuropsychopharmacol Biol Psychiatry20113541002100821315787
   PubMed Web of Science ®Google Scholar
• PandinaGLaneRGopalSA double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophreniaProg Neuropsychopharmacol Biol Psychiatry201135121822621092748
   PubMed Web of Science ®Google Scholar
• FleischhackerWWGopalSLaneRA randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophreniaInt J Neuropsychopharmacol201215110711821777507
   PubMed Web of Science ®Google Scholar
• AlphsLBossieCASliwaJKFuDJMaYWHulihanJPaliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychoticsNeuropsychiatr Dis Treat2013934135023493643
   PubMed Web of Science ®Google Scholar
• FuDJBossieCAKern SliwaJMaYWAlphsLPaliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimensClin Schizophr Relat Psychoses20148210110923446197
   PubMedGoogle Scholar
• GopalSXuHBossieCIncidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databasesInt J Clin Pract201468121514152225358867
   PubMed Web of Science ®Google Scholar
• CoppolaDLiuYGopalSA one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophreniaBMC Psychiatry2012281226
   Google Scholar
• SliwaJKBossieCAFuDJTurkozIAlphsLLong-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophreniaNeuropsychiatr Dis Treat2012837538522956873
   PubMed Web of Science ®Google Scholar
• SchreinerABergmansPCherubinPA prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agentsClin Ther201436101372138825444566
   PubMed Web of Science ®Google Scholar
• AlphsLMaoLRodriguezSCHulihanJStarrHLDesign and rationale of the paliperidone palmitate research in demonstrating effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophreniaJ Clin Psychiatry201475121388139325375367
   PubMed Web of Science ®Google Scholar
• HargarterLCherubinPBergmansPIntramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychoticsProg Neuropsychopharmacol Biol Psychiatry201458C1725448776
   PubMed Web of Science ®Google Scholar
• ZhangFSiTChiouCFEfficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophreniaNeuropsychiatr Dis Treat20151165766825792835
   PubMed Web of Science ®Google Scholar
• KaneJMGarcia-RiberaCClinical guideline recommendations for antipsychotic long-acting injectionsBr J Psychiatry Suppl2009526367
   PubMedGoogle Scholar
• HeresSReichhartTHamannJMendelRLeuchtSKisslingWPsychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophreniaEur Psychiatry20113329730120570493
   PubMed Web of Science ®Google Scholar
• KirschnerMTheodoridouAFusar-PoliPKaiserSJägerMPatients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosisTher Adv Psychopharmacol201332899924167680
   PubMedGoogle Scholar
• ParelladaEVelliganDIEmsleyRKisslingWLong-acting injectable antipsychotics in first-episode schizophreniaSchizophr Res Treatment2012201231853522966433
   PubMedGoogle Scholar
• TaylorMNgKYShould long-acting (depot) antipsychotics be used in early schizophrenia? A systematic reviewAust N Z J Psychiatry201347762463023209308
   PubMed Web of Science ®Google Scholar
• EmsleyRChilizaBAsmalLMashileMFusar-PoliPLong-acting injectable antipsychotics in early psychosis: a literature reviewEarly Interv Psychiatry20137324725423342964
   PubMed Web of Science ®Google Scholar
• HeresSLambertMVauthRTreatment of early episode in patients with schizophrenia: the role of long acting antipsychoticsEur Psychiatry201429suppl 21409141325455704
   PubMed Web of Science ®Google Scholar
• KimBLeeSHYangYKParkJIChungYCLong-acting injectable antipsychotics for first-episode schizophrenia: the pros and consSchizophr Res Treatment2012201256083622966439
   PubMedGoogle Scholar
• MallaATibboPChuePLong-acting injectable antipsychotics: recommendations for cliniciansCan J Psychiatry2013585 suppl 130S35S23945065
   PubMed Web of Science ®Google Scholar
• MaoLAlphsLBensonCFastenauJLynn StarrHCorrelates of repeat arrests/incarcerations in adult subjects diagnosed with schizophrenia with history of criminal justice system (CJS) involvementPoster presented at: APA 167th MeetingMay 3–7, 2014New York, USA
   Google Scholar
• CañasFMöllerHJLong-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability reviewExpert Opin Drug Saf20109568369720690885
   PubMed Web of Science ®Google Scholar
• GeertsPMartinezGSchreinerAAttitudes towards the administration of long-acting antipsychotics: a survey of physicians and nursesBMC Psychiatry2013135823414331
   PubMed Web of Science ®Google Scholar
• ManchandaRChuePMallaALong-acting injectable antipsychotics: evidence of effectiveness and useCan J Psychiatry2013585 suppl 15S13S23945067
   PubMed Web of Science ®Google Scholar
• PatelMHaddadPChaudhryIMcLoughlinSDavidAPsychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 yearsJ Psychopharmacol201024101473148219477883
   PubMed Web of Science ®Google Scholar